NASDAQ:SAGE • US78667J1088
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SAGE THERAPEUTICS INC (SAGE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-07-08 | ScotiaBank | Downgrade | Sector Outperform -> Sector Perform |
| 2025-06-20 | Baird | Maintains | Neutral -> Neutral |
| 2025-06-17 | Truist Securities | Maintains | Hold -> Hold |
| 2025-06-17 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-06-17 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-06-17 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-06-16 | Needham | Reiterate | Hold -> Hold |
| 2025-04-30 | Needham | Reiterate | Hold -> Hold |
| 2025-04-25 | Needham | Reiterate | Hold -> Hold |
| 2025-02-12 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-02-12 | Needham | Reiterate | Hold -> Hold |
| 2025-02-12 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-02-12 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-01-02 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-16 | Stifel | Maintains | Hold -> Hold |
| 2024-11-21 | TD Cowen | Maintains | Hold -> Hold |
| 2024-11-21 | RBC Capital | Upgrade | Underperform -> Sector Perform |
| 2024-11-20 | Needham | Reiterate | Hold |
| 2024-11-20 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-30 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-10-30 | Needham | Reiterate | Hold |
| 2024-10-30 | Oppenheimer | Maintains | Perform -> Perform |
| 2024-10-30 | Truist Securities | Maintains | Hold -> Hold |
| 2024-10-30 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.7M 22.22% | 86.455M 1,022.79% | 41.243M -52.30% | 83.969M 103.60% | 120.02M 42.93% | 158.71M 32.24% | 192M 20.98% | 233.65M 21.69% | 243.67M 4.29% | 249.53M 2.40% | 257.14M 3.05% | |
| EBITDA YoY % growth | -545.9M -19.53% | -545.07M 0.15% | -409.485M 24.87% | -245.645M 40.01% | -208.584M 15.09% | -120.308M 42.32% | -63.597M 47.14% | -18.36M 71.13% | 46.614M 353.89% | N/A | N/A | |
| EBIT YoY % growth | -547M -18.68% | -546.463M 0.10% | -410.516M 24.88% | -246.86M 39.87% | -215.671M 12.63% | -175.659M 18.55% | -122.397M 30.32% | -70.572M 42.34% | -80.399M -13.92% | -84.459M -5.05% | 23.584M 127.92% | |
| Operating Margin | -7,103.90% | -632.08% | -995.36% | -293.99% | -179.70% | -110.68% | -63.75% | -30.20% | -32.99% | -33.85% | 9.17% | |
| EPS YoY % growth | -8.98 -15.13% | -10.31 -14.81% | -6.59 36.08% | -3.67 44.26% | -2.94 20.06% | -2.00 31.89% | -1.35 32.30% | -0.65 51.98% | -1.98 -204.31% | -1.95 1.55% | 0.22 111.52% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.84 45.07% | -0.81 48.23% | -0.78 22.84% | -0.76 3.81% | -0.78 7.77% | -0.77 4.64% |
| Revenue Q2Q % growth | 24.752M 108.51% | 26.922M 110.08% | 25.458M 81.03% | 27.489M -13.17% | 29.682M 19.92% | 32.589M 21.05% |
| EBITDA Q2Q % growth | -62.091M 38.10% | -61.114M 22.94% | -52.032M 22.14% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -57.582M 43.10% | -56.388M 29.81% | -55.767M 16.69% | -59.129M -8.99% | -59.568M -3.45% | -59.225M -5.03% |
All data in USD
17 analysts have analysed SAGE and the average price target is 8.67 USD. This implies a price decrease of -0.09% is expected in the next year compared to the current price of 8.68.
SAGE THERAPEUTICS INC (SAGE) will report earnings on 2025-10-27, before the market open.
The consensus EPS estimate for the next earnings of SAGE THERAPEUTICS INC (SAGE) is -0.84 USD and the consensus revenue estimate is 24.75M USD.
The consensus rating for SAGE THERAPEUTICS INC (SAGE) is 69.4118 / 100 . This indicates that analysts generally have a neutral outlook on the stock.